Designing effective oligonucleotide therapeutics for clinical applications involves understanding both the chemistry and biology of nucleic acids. In this white paper, learn about recent advances in chemical modifications for oligonucleotide therapeutics that improve stability and selectivity, biological screening assays to support lead optimization, and bioanalytical platforms that address the challenges of quantifying oligonucleotides. Check out …Read More >

Download our whitepaper on how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle. Discover fresh opportunities to characterize challenging drug targets, examine biophysical screening methods, and look toward what’s next for biophysical methods in drug discovery.

Chronic neurodegenerative diseases encompass a variety of progressive conditions that affect neurons, including Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and other forms of dementia. They are among the most common and challenging central nervous system (CNS) diseases. “Many companies had stopped their research program into neurodegenerative diseases, but now sophisticated technology advances have became more broadly …Read More >